Clinical and Preclinical Modulation of Chemotherapy-Induced Toxicity in Patients with Cancer
Authors:
- 1 January 1999
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 57 (2) , 133-155
Abstract
Anticancer treatment is generally associated with toxicity to health issues. One of the reasons for this unpleasant association is that anticancer agents have been mostly selected on the basis of an...Keywords
This publication has 100 references indexed in Scilit:
- Flavonoids as Scavengers of Nitric Oxide RadicalBiochemical and Biophysical Research Communications, 1995
- Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of actionCarcinogenesis, 1995
- Amifostine Plus Granulocyte Colony-stimulating Factor Therapy Enhances Recovery from Supralethal Radiation Exposures: Preclinical Experience in Animal ModelsEuropean Journal of Cancer, 1995
- A Review of the Use of Chemoprotectants in Cancer ChemotherapyDrug Safety, 1994
- Nerve growth factor prevents neurotoxic effects of cisplatin, vincristine and taxol, on adult rat sympathetic ganglion explants in vitroLife Sciences, 1994
- Outcome of clinical congestive heart failure induced by anthracycline chemotherapyCancer, 1992
- Biochemical modification of the toxicity and the anti-tumour effect of 5-fluorouracil and cis-platinum by WR-2721 in miceEuropean Journal of Cancer, 1992
- Prevention of Cisplatin Neurotoxicity with an ACTH(4–9) Analogue in Patients with Ovarian CancerNew England Journal of Medicine, 1990
- Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapyThe American Journal of Medicine, 1987
- Adriamycin: The Role of Lipid Peroxidation in Cardiac Toxicity and Tumor ResponseScience, 1977